National Cancer Institute; Amended Notice of Meeting, 46357 [2013-18326]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 147 / Wednesday, July 31, 2013 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
• HHS Reference No. E–128–2006—
PCT Application No. PCT/US2007/
071412.
Licensing Contact: Charlene Sydnor,
Ph.D.; 301–435–4689;
sydnorc@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute on Drug Abuse is
seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize
Potent and Selective Analogues of
Modafinil and Uses Thereof. For
collaboration opportunities, please
contact Michelle Kim Leff, MD, MBA at
mleff@mail.nih.gov.
Translocator Protein 18 kDa PET
Radioligands With High Affinities
Regardless of Genotype
Description of Technology: This
technology relates to a group of
Translocator protein 18 kDa (TSPO)
radioligands for Positron Emission
Tomography (PET) that are specific and
accurate, regardless of genotype. TSPO
is a mitochondrial protein expressed in
inflammatory cells, which is a marker
for neuroinflammation.
Neuroinflammation is symptomatic of
many neuropsychiatric and
neurodegenerative disorders, such as
multiple sclerosis, stroke, epilepsy,
dementia, and traumatic brain injuries.
Monitoring and quantifying TSPO 18
kDa with radioligands in PET may have
clinical application in understanding,
diagnosing and treating many
neuropsychiatric disorders. However,
current TSPO 18 kDa radioligands either
lack specificity or, due to TSPO
polymorphisms, have highly variable
inter-subject sensitivities depending on
genotype. These new ligands are
specific and accurate, regardless of
genotype, allowing simplified
interpretation and quantification of the
binding signal.
Potential Commercial Applications:
Biomarker or diagnostic for
neuroinflammation
Competitive Advantages: Specific and
accurate, regardless of genotype
Development Stage:
• Early-stage
• Pre-clinical
• In vivo data available (animal)
Inventors: Robert B. Innis, Victor W.
Pike, Sam S. Zoghbi, Yi Zhang (NIMH);
Sabrina Castellano (University of
Salerno, Italy); Giorgio Stefancich
(University of Trieste, Italy); Sabrina
Talia, Federico Da Settimo, Claudia
Martini (University of Pisa, Italy)
Publications:
1. Oh U, et al. Translocator protein
PET imaging for glial activation in
multiple sclerosis. J Neuroimmune
VerDate Mar<15>2010
16:14 Jul 30, 2013
Jkt 229001
46357
Pharmacol. 2011 Sep;6(3):354–61.
[PMID 20872081]
2. Kreisl WC, et al. Stroke incidentally
identified using improved positron
emission tomography for microglial
activation. Arch Neurol. 2009
Oct;66(1):1288–9. [PMID 19822787]
3. Hirvonen J, et al. Increased in vivo
expression of an inflammatory marker
in temporal lobe epilepsy. J Nucl Med.
2012 Feb;53(2):234–40. [PMID
22238156]
4. Kreisl WC, et al. In vivo radioligand
binding to translocator protein
correlates with severity of Alzheimer’s
disease. Brain. 2013 Jul;136(Pt 7):2228–
38. [PMID 23775979]
Intellectual Property: HHS Reference
No. E–262–2012/0—U.S. Provisional
Patent Application No. 61/777, 542 filed
March 12, 2013
Licensing Contact: Edward (Tedd)
Fenn, J.D.; 424–500–2005;
Tedd.fenn@nih.gov.
Collaborative Research Opportunity:
The National Institute of Mental Health
is seeking statements of capability or
interest from parties interested in
collaborative research to further
develop, evaluate or commercialize
TSPO radioligands for monitoring
inflammation. For collaboration
opportunities, please contact Suzanne
Winfield at winfiels@mail.nih.gov.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Clinical Trial
Implementation Cooperative Agreement
(U01).
Date: August 26, 2013.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Betty Poon, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
NIAID/NIH/DHHS, 6700B Rockledge Drive,
MSC 7616, Bethesda, MD 20892–7616, (301)
402–6891, poonb@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: July 25, 2013.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
National Institutes of Health
[FR Doc. 2013–18329 Filed 7–30–13; 8:45 am]
Notice is hereby given of a change in
the teleconference meeting of the
National Cancer Institute Board of
Scientific Advisors ad hoc
Subcommittee on HIV/AIDS
Malignancy, August 08, 2013, 10:30 a.m.
to 12:00 p.m., National Cancer Institute,
NIH, Building 10, Room 10S255, 10
Center Drive, Bethesda, MD 20892
which was published in the Federal
Register on July 24, 2013, 78FR44577.
This meeting notice is amended to
provide a change in location for the
public. The location for the public is
National Cancer Institute Shady Grove,
9609 Medical Center Drive, Seventh
Floor, West Tower, Room 7W034,
Rockville, MD 20850. As previously
indicated, members of the public may
also dial-in to the teleconference using
the following number: 866–492–1791.
The meeting is open to the public.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
PO 00000
Frm 00046
Fmt 4703
Sfmt 9990
Dated: July 25, 2013.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–18327 Filed 7–30–13; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Cancer Institute; Amended
Notice of Meeting
Dated: July 25, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2013–18326 Filed 7–30–13; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\31JYN1.SGM
31JYN1
]]>Agencies
[Federal Register Volume 78, Number 147 (Wednesday, July 31, 2013)]
[Notices]
[Page 46357]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-18326]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended Notice of Meeting
Notice is hereby given of a change in the teleconference meeting of
the National Cancer Institute Board of Scientific Advisors ad hoc
Subcommittee on HIV/AIDS Malignancy, August 08, 2013, 10:30 a.m. to
12:00 p.m., National Cancer Institute, NIH, Building 10, Room 10S255,
10 Center Drive, Bethesda, MD 20892 which was published in the Federal
Register on July 24, 2013, 78FR44577.
This meeting notice is amended to provide a change in location for
the public. The location for the public is National Cancer Institute
Shady Grove, 9609 Medical Center Drive, Seventh Floor, West Tower, Room
7W034, Rockville, MD 20850. As previously indicated, members of the
public may also dial-in to the teleconference using the following
number: 866-492-1791. The meeting is open to the public.
Dated: July 25, 2013.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2013-18326 Filed 7-30-13; 8:45 am]
BILLING CODE 4140-01-P
